Navigation Links
CSRA's DynPort Vaccine Company to Help Advance Medical Products for the National Institute of Allergy and Infectious Diseases
Date:12/27/2016

FALLS CHURCH, Va., Dec. 27, 2016 /PRNewswire/ -- CSRA Inc.'s (NYSE: CSRA) wholly-owned subsidiary, DynPort Vaccine Company LLC (DVC), received a multiple-award, indefinite-delivery, indefinite-quantity (IDIQ) contract to manage a variety of medical product development initiatives for the National Institute of Allergy and Infectious Diseases (NIAID). CSRA's DynPort Vaccine Company is one of four awardees to receive the IDIQ valued up to $159 million, with a period of performance of up to 10 years.

Under the contract, the company will develop manufacturing processes and analytical test methods, perform product characterization, conduct manufacturing following current good manufacturing practices (cGMP) and provide regulatory services to support the development of new therapies to treat infectious diseases. NIAID is part of the National Institutes of Health and focuses on understanding, treating and preventing infectious, immunologic and allergic diseases that impact our nation and the world.

"DVC has been successfully conducting product development for government agencies for nearly 20 years," said Gary S. Nabors, Ph.D., President, DynPort Vaccine Company LLC. "Together with our teaming partners, we have the talent and experience base to conduct the wide array of medical product development activities needed by our customer. NIAID has been at the forefront of implementing new therapies, vaccines, diagnostic tests and other technologies that have improved the lives of millions of people around the world and we are honored to support their efforts."
This project will be funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract No. HHSN272201600005I.

About CSRA Inc.
Every day CSRA (NYSE: CSRA) makes a difference in how the government serves our country and our citizens. We deliver a broad range of innovative, cloud-enabled, next-generation IT solutions and professional services to help our customers modernize their legacy systems, protect their applications, infrastructure, and assets and improve the effectiveness and efficiency of mission-critical functions for our warfighters and our citizens. Our 18,000 employees understand that success is a matter of perseverance, courage, adaptability and experience. CSRA is headquartered in Falls Church, Virginia. To learn more about CSRA, visit www.csra.com.

Forward-looking Statements
All statements in this press release and in all future press releases that do not directly and exclusively relate to historical facts constitute "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements represent CSRA's intentions, plans, expectations and beliefs, including statements about network and asset protection and improving mission-critical functions. The forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside the control of CSRA. These factors could cause actual results to differ materially from forward-looking statements. For a written description of these factors, see the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in CSRA's most recent Annual Report on Form 10-K and any updating information in subsequent SEC filings. CSRA disclaims any intention or obligation to update these forward-looking statements whether as a result of subsequent event or otherwise, except as required by law.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/csras-dynport-vaccine-company-to-help-advance-medical-products-for-the-national-institute-of-allergy-and-infectious-diseases-300383366.html


'/>"/>
SOURCE CSRA Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Research Team Publishes New Methods for Synthetic Generation of Influenza Vaccines
2. Cancer Vaccine Partnering Terms and Agreements
3. A*STAR and Cytos Bring Singapores First Influenza Vaccine to Clinical Testing
4. Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak
5. iBio Technology Produces Vaccine Candidate for Recently Emerged H7N9 Influenza
6. Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine
7. Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine
8. Goodwin Biotechnology Announces Process Development Sub-Contract for an Anthrax Vaccine
9. Generex Announces ASCO Presentations of AE37 Vaccine Data; Potential Leading Immunotherapy Option for Breast Cancer Patients
10. Adult and Adolescent Vaccines Market to 2018 Report - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth
11. ASCO Interview of MD Andersons Mittendorf on AE37 Breast Cancer Vaccine Now Available on Generex Websites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... 2017 The Bio Supply Management Alliance (BSMA) ... Fremont and the Biomedical Manufacturing Network to ... California by providing a platform ... fostering workforce development. The primary focus of this alliance ... as well as small and mid-sized biomedical companies. ...
(Date:6/12/2017)... SEATTLE , June 12, 2017 Kineta, Inc., ... today announced Kineta Vice President of R&D and ... at the Pandemic Preparedness for the Northwest and Beyond ... be held on June 14, 2017 from 8:30-10:30 AM PDT ... Dr. Bedard will be joined ...
(Date:6/9/2017)... AirXpanders, Inc. (ASX: AXP) (AirXpanders or Company), ... sale and distribution of the AeroForm® Tissue Expander System, ... commercial roll-out in the United States ... hundred (100) medical institutions and health systems, located throughout ... alternative for women who choose reconstructive surgery following a ...
Breaking Medicine Technology:
(Date:6/27/2017)... , ... June 27, 2017 , ... ... Fabrykiewicz Scholarship Foundation Fundraiser hygiene symposium in Mystic, CT. Covering the process and ... offered their experience in these popular periodontal procedures. Drs. Toback and Urbanski practice ...
(Date:6/27/2017)... CA (PRWEB) , ... June 27, 2017 , ... Today, ... 2001 suffer from PTSD. Yet less than 20% will receive adequate care due to ... with PTSD won't receive any care at all. And left untreated, veterans are at ...
(Date:6/27/2017)... ... ... Children’s National Health System received top honors in the 2017-18 U.S News & ... of more than 1500 neonatal intensive care units coast to coast. Children’s ... the top performing children’s hospitals in the country. , In addition to achieving ...
(Date:6/26/2017)... ... June 26, 2017 , ... ... & Sexual Medicine Specialists, in collaboration with the Fertility Center of California, is ... care: PESA (percutaneous epidydimal sperm aspiration) and TESA (percutaneous testicular sperm extraction). These ...
(Date:6/26/2017)... ... June 26, 2017 , ... A new ... the way women look and feel about themselves and their sexual encounters. A ... dysfunction and urinary leakage head on with a ground breaking medical technique aimed ...
Breaking Medicine News(10 mins):